Pfizer Inc. (PFE)

36.38
NYSE : Health Technology
Prev Close 36.50
Day Low/High 36.26 / 36.72
52 Wk Low/High 33.97 / 46.47
Avg Volume 25.42M
Exchange NYSE
Shares Outstanding 5.53B
Market Cap 201.88B
EPS 1.90
P/E Ratio 16.44
Div & Yield 1.44 (3.86%)
Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

PFE was ready to pay $160 billion until U.S. regulators blocked the deal.

European Commission Approves TALZENNA® (talazoparib) For Patients With Inherited (Germline) BRCA-Mutated Locally Advanced Or Metastatic Breast Cancer

European Commission Approves TALZENNA® (talazoparib) For Patients With Inherited (Germline) BRCA-Mutated Locally Advanced Or Metastatic Breast Cancer

Pfizer Inc. (NYSE:PFE) today announced that the European Commission approved TALZENNA ® (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility...

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

These two firms have successful drugs and could make nice additions for larger companies.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition

SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition

NEW YORK, June 18, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Array BioPharma ("Array" or the "Company") (NASDAQ: ARRY) in connection with the proposed...

Pfizer Invites Public To View And Listen To Webcast Of July 30 Conference Call With Analysts

Pfizer Invites Public To View And Listen To Webcast Of July 30 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.

Fed Up, Yet?

The narrative in the market is that we are waiting for the Fed decision on Wednesday -- but of course it's not that clear cut is it?

Stocks End Slightly Higher in Cautious Trading Ahead of Federal Reserve Meeting

Stocks End Slightly Higher in Cautious Trading Ahead of Federal Reserve Meeting

Stocks end moderately ahead as investors are adopting a cautious stance heading into this week's Federal Reserve meeting.

Bulls Walk the Market Up Slowly, but Keep One Eye on Fed

Bulls Walk the Market Up Slowly, but Keep One Eye on Fed

I'm inclined to add to Disney on today's weakness.

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.

UniQure Jumps on Report It's Exploring a Possible Sale

UniQure Jumps on Report It's Exploring a Possible Sale

A report says the biotechnology company is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy.

Pfizer To Acquire Array BioPharma

Pfizer To Acquire Array BioPharma

- Proposed acquisition strengthens Pfizer's innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term

Pfizer To Acquire Array BioPharma

Pfizer To Acquire Array BioPharma

Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc.

How to Invest in Stocks: 14 Keys to Remember

How to Invest in Stocks: 14 Keys to Remember

Larry Swedroe lays out the fundamental truths of investing -- for beginners.

Pfizer Announces Results From XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study To Evaluate Methotrexate Withdrawal With A JAK Inhibitor

Pfizer Announces Results From XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study To Evaluate Methotrexate Withdrawal With A JAK Inhibitor

Pfizer Inc. (NYSE:PFE) announced today positive results from ORAL Shift, a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis (RA).

Great News In An Oversold Market: Cramer's 'Mad Money' Recap (Friday 6/7/19)

Great News In An Oversold Market: Cramer's 'Mad Money' Recap (Friday 6/7/19)

It was a great week for stocks, says Jim Cramer. And he's got your game plan for next week.

PFIZER INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates The Officers And Directors Of Pfizer Inc. - PFE

PFIZER INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates The Officers And Directors Of Pfizer Inc. - PFE

NEW ORLEANS, June 7, 2019 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.

PayPal, Tesla, Pfizer: 'Mad Money' Lightning Round

PayPal, Tesla, Pfizer: 'Mad Money' Lightning Round

Jim Cramer takes a look at PayPal, Tesla, Pfizer, Americold Realty Trust, Continental Resources, United Natural Foods, Cintas, Splunk and more.

Jeff Settleman, Ph.D., Joins Pfizer To Lead Oncology Research & Development

Jeff Settleman, Ph.D., Joins Pfizer To Lead Oncology Research & Development

Pfizer Inc. (NYSE: PFE) announced today that Jeff Settleman, Ph.

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #16 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Despite being ranked lower than the median among analyst picks of the Dow, Pfizer Inc ranks better than the median among analyst picks for the broader S&P 500 index components, claiming the #205 spot out of 500.

Pfizer Announces Top-Line Results From Phase 3 Trial Of LYRICA® (pregabalin) In Primary Generalized Tonic-Clonic Seizures

Pfizer Announces Top-Line Results From Phase 3 Trial Of LYRICA® (pregabalin) In Primary Generalized Tonic-Clonic Seizures

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA ® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary...

Pfizer Gains After Being Named 'Top Pick' by Credit Suisse

Pfizer Gains After Being Named 'Top Pick' by Credit Suisse

Shares of Pfizer rise Thursday after the drugmaker is named a 'top pick' at Credit Suisse following a meeting the analysts had with Pfizer's management team.

Pfizer Oncology To Showcase New Data From Innovative Science That Address Patient Needs At ASCO 2019 Annual Meeting

Pfizer Oncology To Showcase New Data From Innovative Science That Address Patient Needs At ASCO 2019 Annual Meeting

Pfizer Inc. (NYSE:PFE) will present data across its industry-leading oncology portfolio, covering multiple tumor types and mechanisms of action at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31-June 4,...

Pfizer Announces Positive Top-Line Results From Phase 3 Study Of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), In Patients Aged 12 And Older With Moderate To Severe Atopic Dermatitis

Pfizer Announces Positive Top-Line Results From Phase 3 Study Of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), In Patients Aged 12 And Older With Moderate To Severe Atopic Dermatitis

Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and...

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Attorneys general from 44 states allege the nation's largest generic drugmakers conspired to artificially inflate and manipulate prices for more than 100 different generic drugs.

TheStreet Quant Rating: B (Buy)